Loading...
Docoh

Genmab (GMAB)

News

From Benzinga Pro
Morgan Stanley Maintains Underweight on Genmab, Lowers Price Target to $29
17 May 22
News, Price Target, Analyst Ratings
Morgan Stanley maintains Genmab (NASDAQ:GMAB) with a Underweight and lowers the price target from $30 to $29.
Analyst Ratings for Genmab
12 May 22
Analyst Ratings
Within the last quarter, Genmab (NASDAQ:GMAB) has observed the following analyst ratings:
SVB Leerink Maintains Market Perform on Genmab, Lowers Price Target to $30
12 May 22
News, Price Target, Analyst Ratings
SVB Leerink analyst Jonathan Chang maintains Genmab (NASDAQ:GMAB) with a Market Perform and lowers the price target from $39 to $30.
Stocks That Hit 52-Week Lows On Wednesday
11 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Wednesday, 807 companies reached new 52-week lows.
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
11 May 22
Biotech, Earnings, Large Cap, News, Penny Stocks, Health Care, Financing, Offerings, Contracts, Small Cap, FDA, Movers, Trading Ideas, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022
2 May 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
Cowen & Co. Initiates Coverage On Genmab with Market Perform Rating, Announces Price Target of $38
2 May 22
News, Price Target, Initiation, Analyst Ratings
Cowen & Co. analyst Yaron Werber initiates coverage on Genmab (NASDAQ:GMAB) with a Market Perform rating and announces Price Target of $38.
Genmab Q1 DARZALEX Net Sales $1.856B
19 Apr 22
News
https://view.news.eu.nasdaq.com/view?id=b2d0138844e6e69116a9259978c6024e2&lang=en
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
14 Apr 22
Biotech, Government, News, Penny Stocks, Health Care, Financing, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
AbbVie - Genmab Post Epcoritamab Data From Early-Stage Blood Cancer Study
14 Apr 22
Biotech, News, Health Care, General
Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV)
Genmab And AbbVie Announce Topline Results For Epcoritamab From Phase 1/2 Trial In Patients With Relapsed/Refractory Large B-Cell Lymphoma
13 Apr 22
News, FDA
Genmab A/S (NASDAQ:GMAB) and AbbVie (NYSE:ABBV) announced today topline results from the first cohort of the EPCORE™ NHL-1 phase 1/2, clinical trial evaluating epcoritamab (DuoBody®-CD3xCD20), an
Morgan Stanley Maintains Underweight on Genmab, Lowers Price Target to $30
12 Apr 22
News, Price Target, Analyst Ratings
Morgan Stanley maintains Genmab (NASDAQ:GMAB) with a Underweight and lowers the price target from $33 to $30.
Janssen Partner Genmab Loses Arbitration Over Darzalex Royalties
8 Apr 22
Biotech, News, Health Care, Legal, Movers, Trading Ideas, General
The Daily Biotech Pulse: Evotec Earns $16M Milestone Payment, Genmab Hit With Adverse Tribunal Ruling, Quidel Announces Above-Consensus Q1 Revenues And More
8 Apr 22
Biotech, Earnings, News, Penny Stocks, Guidance, Small Cap, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
Genmab Announced the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement
7 Apr 22
News, Legal
Genmab A/S (Nasdaq: GMAB) announced today an award in the binding arbitration of two matters arising under its license agreement with Janssen Biotech, Inc. (Janssen) relating to daratumumab. The arbitral tribunal issued an award on April 7, 2022, deciding both issues in favor of Janssen.
Genmab Announces FDA Granted Orphan-Drug Designation To Epcoritamab In Follicular Lymphoma
8 Mar 22
Biotech, News, FDA, General
Orphan drug status is designated by the FDA to medicines and biologics that are defined as those intended for the prevention, diagnosis, or treatment of a rare disease or condition affecting less than 200,000 people in
Genmab Granted FDA Orphan Drug Designation Monday for Treatment of Follicular Lymphoma
2 Mar 22
News, FDA
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=865921

Press releases

From Benzinga Pro
Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress
12 May 22
Press Releases
Multiple epcoritamab (DuoBody®-CD3xCD20) studies will be presented showcasing preliminary efficacy and safety findings in a variety of patient populations in need of treatment options Several abstracts
AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
13 Apr 22
Press Releases
- Based on topline results from the EPCORE™ NHL-1 clinical trial, AbbVie and Genmab will engage global regulatory authorities- Data from the clinical trial to be presented at a future medical
Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
13 Apr 22
Press Releases
Company Announcement Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage global regulatory authorities to discuss next steps Data from the clinical trial to be
Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement
7 Apr 22
Press Releases
Company Announcement COPENHAGEN, Denmark; April 8, 2022 – Genmab A/S (NASDAQ:GMAB) announced today an award in the binding arbitration of two matters arising under its license agreement with Janssen Biotech, Inc.
Genmab Announces U.S. Food and Drug Administration Granted Orphan-Drug Designation to Epcoritamab (DuoBody®-CD3xCD20) in Follicular Lymphoma
8 Mar 22
Press Releases
Genmab A/S (NASDAQ:GMAB) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to the investigational medicine, epcoritamab (DuoBody®-CD3xCD20), for the treatment of